1.00Open1.00Pre Close0 Volume5 Open Interest145.00Strike Price0.00Turnover23.23%IV5.88%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry1.00Extrinsic Value100Contract SizeAmericanOptions Type0.2199Delta0.0363Gamma137.89Leverage Ratio-0.0546Theta0.0190Rho30.32Eff Leverage0.1039Vega
Wintrust Financial Stock Discussion
Wintrust Financial is gearing up to report its quarterly earnings on Monday, and analysts are anticipating a strong performance. The company is expected to surpass market expectations, potentially triggering a significant bullish run.
The Power of a Strong Earnings Report
A positive earnings report can have a profound impact on a company's stock price. It can transform a relatively unknown or overlooked company into a major m...
Wintrust Financial
Positive Indicators:
+ Strong Regional Economy: Wintrust Financial operates primarily in the Midwest, a region that has shown resilience and growth in recent quarters. This economic strength can directly impact the bank's loan portfolio and deposit base.
+ Increased Lending Activity: Rising interest rates have generally led to increased lending activity, which can boost Wintrust's revenue and net int...
NEWS
Wintrust Financial Corporation and Macatawa Bank Corporation Announce Plans to Merge
Wintrust Financial and Macatawa Bank have announced a merger agreement for Wintrust to acquire Macatawa in an all-stock transaction. Macatawa, with approximately $2.7 billion in assets, will be acquired for an estimated $510.3 million, or $14.85 per share. The transaction is expected to close in the second half of 2024.
• $DBV Technologies (DBVT.US)$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $Aldeyra Therapeutics (ALDX.US)$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $MediciNova (MNOV.US)$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $Torrid (CURV.US)$ +11% (In reaction to earnings/guidance)
• $Novavax (NVAX.US)$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...
No comment yet